About OmniAb
Offering best-in-class therapeutic antibody discovery technologies since 2012
Ligand Pharmaceuticals’ OmniAb provides the industry’s only offering with multiple transgenic animal species, strategically built to optimally harness the unparalleled power of Biological Intelligence. Beginning with OmniRat® in 2012, this suite of animal technologies has expanded over the years with the addition of OmniFlic® and OmniMouse® in 2014, OmniChicken® in 2016, OmniClic® in 2019, and OmniTaur™ in 2020.
In 2020, OmniAb’s offerings also broadened to include antigen design and other technologies that supplement the animal offerings. As a leader in transgenic animal technology, we are committed to providing technologies that enable and enhance the discovery of therapeutic antibodies
partner |
program |
platform |
area |
phase 1 |
phase 2 |
phase 3 |
registration |
approved |
|---|---|---|---|---|---|---|---|---|
| Gloria Pharmaceuticals Arcus Biosciences |
Zimberelimab | OmniRat | Oncology | |||||
| CStone Pharmaceuticals | Sugemalimab | OmniRat | Oncology | |||||
| Janssen | Teclistamab | OmniRat | Oncology | |||||
| Genentech | Tiragolumab | OmniRat | Oncology | |||||
| Hanall Biopharma Immunovant Harbour BioMed |
Batoclimab | OmniRat | Immunology | |||||
| Genmab | GEN1046 | OmniRat | Oncology | |||||
| Undisclosed | OmniRat | Undisclosed | ||||||
| Genmab | GEN1047 | OmniRat | Oncology | |||||
| Aptevo Therapeutics | APVO436 | OmniMouse | Oncology | |||||
| Janssen | JNJ-67371244 | OmniMouse | Oncology | |||||
| Janssen | JNJ-70218902 | OmniRat | Oncology | |||||
| Janssen | JNJ-8306358 | OmniRat | Oncology | |||||
| Merck | M6223 | OmniRat | Oncology | |||||
| Symphogen | SYM022 | OmniRat | Oncology | |||||
| Symphogen | SYM023 | OmniRat | Oncology | |||||
| Symphogen | SYM024 | OmniRat | Oncology | |||||
| Symphogen | S095029 | OmniRat | Oncology | |||||
| AbbVie | TNB-383B | OmniFlic | Oncology | |||||
| Ancora | TNB-486 | OmniFlic | Oncology | |||||
| Amgen | AMG 340 | OmniFlic | Oncology | |||||
| SalubrisBio | SAL003 | OmniRat | Metabolic | |||||
| Boehringer Ingelheim | Undisclosed | OmniChicken | Undisclosed | |||||
| Curon | CN1 | OmniRat | Oncology | |||||
| Zhilkang Hongyi | Undisclosed | OmniRat | Undisclosed | |||||
| Undisclosed | OmniRat | Undisclosed | ||||||
| Partner | Gloria Pharmaceuticals Arcus Biosciences |
|---|---|
| Program | Zimberelimab |
| Platform | OmniRat |
| Area | Oncology |
| Phase | Approved |
| Partner | CStone Pharmaceuticals |
| Program | Sugemalimab |
| Platform | OmniRat |
| Area | Oncology |
| Phase | Approved |
| Partner | Janssen |
| Program | Teclistamab |
| Platform | OmniRat |
| Area | Oncology |
| Phase | Registration |
| Partner | Genentech |
| Program | Tiragolumab |
| Platform | OmniRat |
| Area | Oncology |
| Phase | Phase 3 |
| Partner | Hanall Biopharma Immunovant Harbour BioMed |
| Program | Batoclimab |
| Platform | OmniRat |
| Area | Immunology |
| Phase | Phase 3 |
| Partner | Genmab |
| Program | GEN1046 |
| Platform | OmniRat |
| Area | Oncology |
| Phase | Phase 2 |
| Partner | |
| Program | Undisclosed |
| Platform | OmniRat |
| Area | Undisclosed |
| Phase | Phase 2 |
| Partner | Genmab |
| Program | GEN1047 |
| Platform | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Aptevo Therapeutics |
| Program | APVO436 |
| Platform | OmniMouse |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Janssen |
| Program | JNJ-67371244 |
| Platform | OmniMouse |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Janssen |
| Program | JNJ-70218902 |
| Platform | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Janssen |
| Program | JNJ-8306358 |
| Platform | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Merck |
| Program | M6223 |
| Platform | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Symphogen |
| Program | SYM022 |
| Platform | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Symphogen |
| Program | SYM023 |
| Platform | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Symphogen |
| Program | SYM024 |
| Platform | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Symphogen |
| Program | S095029 |
| Platform | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | AbbVie |
| Program | TNB-383B |
| Platform | OmniFlic |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Ancora |
| Program | TNB-486 |
| Platform | OmniFlic |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Amgen |
| Program | AMG 340 |
| Platform | OmniFlic |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | SalubrisBio |
| Program | SAL003 |
| Platform | OmniRat |
| Area | Metabolic |
| Phase | Phase 1 |
| Partner | Boehringer Ingelheim |
| Program | Undisclosed |
| Platform | OmniChicken |
| Area | Undisclosed |
| Phase | Phase 1 |
| Partner | Curon |
| Program | CN1 |
| Platform | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Zhilkang Hongyi |
| Program | Undisclosed |
| Platform | OmniRat |
| Area | Undisclosed |
| Phase | Phase 1 |
| Partner | |
| Program | Undisclosed |
| Platform | OmniRat |
| Area | Undisclosed |
| Phase | Phase 1 |